These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23661334)

  • 21. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.
    Klempner SJ; Cohen DW; Costa DB
    J Thorac Oncol; 2011 Aug; 6(8):1439-40. PubMed ID: 21847065
    [No Abstract]   [Full Text] [Related]  

  • 23. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
    To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
    J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.
    Kim RN; Choi YL; Lee MS; Lira ME; Mao M; Mann D; Stahl J; Licon A; Choi SJ; Van Vrancken M; Han J; Wlodarska I; Kim J
    Cancer Res Treat; 2016 Jan; 48(1):398-402. PubMed ID: 25715771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
    Takeuchi K; Choi YL; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Takada S; Yamashita Y; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y; Mano H
    Clin Cancer Res; 2008 Oct; 14(20):6618-24. PubMed ID: 18927303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
    Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
    J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [ALK gene fusion associated non-small cell lung cancer: automated immunostainer detection and clinicopathologic perspectives].
    Shen Q; Pan Y; Yu B; Shi S; Liu B; Xu Y; Wang Y; Xia Q; Rao Q; Lu Z; Shi Q; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):164-9. PubMed ID: 26268749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
    Allen JM; Schrock AB; Erlich RL; Miller VA; Stephens PJ; Ross JS; Ou SI; Ali SM; Vafai D
    Clin Lung Cancer; 2017 May; 18(3):e219-e222. PubMed ID: 28089157
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.
    Ren H; Hou X; Eiken PW; Zhang J; Pierson KE; Nair AA; Davila JI; Kovarikova H; Jang JS; Johnson SH; Molina JR; Marks RS; Yang P; Yi JE; Mansfield AS; Jen J
    Clin Lung Cancer; 2019 Mar; 20(2):e142-e147. PubMed ID: 30581091
    [No Abstract]   [Full Text] [Related]  

  • 38. A Rare Fusion of CLIP1 and ALK in a Case of Non-Small-Cell Lung Cancer With Neuroendocrine Features.
    Pinsolle J; Mondet J; Duruisseaux M; d'Alnoncourt S; Magnat N; de Fraipont F; Moro-Sibilot D; Toffart AC; Brambilla E; McLeer-Florin A
    Clin Lung Cancer; 2019 Sep; 20(5):e535-e540. PubMed ID: 31171381
    [No Abstract]   [Full Text] [Related]  

  • 39. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel fusion of TPR and ALK in lung adenocarcinoma.
    Choi YL; Lira ME; Hong M; Kim RN; Choi SJ; Song JY; Pandy K; Mann DL; Stahl JA; Peckham HE; Zheng Z; Han J; Mao M; Kim J
    J Thorac Oncol; 2014 Apr; 9(4):563-6. PubMed ID: 24736082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.